Ecrins Therpeutics developes a drug candidate ET-D5 which is a First-in-Class small molecule with an original anti-vascular and anti-proliferative mechanism of action. The company aims to develop its drug candidates to clinical Proof of Concept;
To get content containing either thought or leadership enter:
To get content containing both thought and leadership enter:
To get content containing the expression thought leadership enter:
You can enter several keywords and you can refine them whenever you want. Our suggestion engine uses more signals but entering a few keywords here will rapidly give you great content to curate.
Ecrins Therpeutics developes a drug candidate ET-D5 which is a First-in-Class small molecule with an original anti-vascular and anti-proliferative mechanism of action. The company aims to develop its drug candidates to clinical Proof of Concept;
www.geg-tech.com/Vectors